[go: up one dir, main page]

MX2017013875A - Ciertos inhibidores de la proteína quinasa. - Google Patents

Ciertos inhibidores de la proteína quinasa.

Info

Publication number
MX2017013875A
MX2017013875A MX2017013875A MX2017013875A MX2017013875A MX 2017013875 A MX2017013875 A MX 2017013875A MX 2017013875 A MX2017013875 A MX 2017013875A MX 2017013875 A MX2017013875 A MX 2017013875A MX 2017013875 A MX2017013875 A MX 2017013875A
Authority
MX
Mexico
Prior art keywords
certain inhibitors
quinasa
protein
protein quinasa
inhibitors
Prior art date
Application number
MX2017013875A
Other languages
English (en)
Other versions
MX395032B (es
Inventor
Weibo Wang
Yang Lijun
Li Tongshuang
Zhao Xingdong
Tan Haohan
Wang Xianlong
Liu Qihong
Jiang Lihua
Liu Yanxin
Lin Min
Sun Jing
Chen Zhifang
LINGHU Li
Chen Ling
Rong Yue
Tan Rui
Zhou Zuwen
Liu Bin
Original Assignee
Chongqing Fochon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57198165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017013875(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chongqing Fochon Pharmaceutical Co Ltd filed Critical Chongqing Fochon Pharmaceutical Co Ltd
Publication of MX2017013875A publication Critical patent/MX2017013875A/es
Publication of MX395032B publication Critical patent/MX395032B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se proporcionan aquí ciertos inhibidores de la CDK4/6, composiciones farmacéuticas de los mismos, y métodos para usarlos.
MX2017013875A 2015-04-28 2016-04-28 Ciertos inhibidores de la proteína quinasa. MX395032B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154082P 2015-04-28 2015-04-28
PCT/CN2016/080475 WO2016173505A1 (en) 2015-04-28 2016-04-28 Certain protein kinase inhibitor

Publications (2)

Publication Number Publication Date
MX2017013875A true MX2017013875A (es) 2018-06-22
MX395032B MX395032B (es) 2025-03-24

Family

ID=57198165

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013875A MX395032B (es) 2015-04-28 2016-04-28 Ciertos inhibidores de la proteína quinasa.

Country Status (10)

Country Link
US (1) US10450316B2 (es)
EP (1) EP3288931B2 (es)
CN (1) CN107849012B (es)
BR (1) BR112017023225A2 (es)
DK (1) DK3288931T4 (es)
ES (1) ES2766498T5 (es)
MX (1) MX395032B (es)
RU (1) RU2732952C2 (es)
TW (1) TWI696617B (es)
WO (1) WO2016173505A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3157916B1 (en) 2014-06-19 2018-12-12 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN106608879A (zh) * 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
EP3559000B1 (en) * 2016-12-22 2022-03-23 Betta Pharmaceuticals Co., Ltd. Benzimidazole derivatives, preparation methods and uses theirof
CN108794452B (zh) 2017-05-05 2021-05-28 上海时莱生物技术有限公司 具有激酶抑制活性的化合物、其制备方法和用途
KR102464677B1 (ko) 2017-08-11 2022-11-10 셍커 파마슈티컬스 (지앙수) 엘티디. 단백질 인산화효소 억제제로 작용하는 1h-피라졸로[4,3-h]퀴나졸린 화합물
US11351170B2 (en) 2017-08-15 2022-06-07 Beijing Xuanyi Pharmasciences Co., Ltd. Substituted pyrimidines as CDK4/6 inhibitors
BR112020023107A2 (pt) 2018-05-14 2021-02-02 Ariad Pharmaceuticals, Inc. sais farmacêuticos de derivados de pirimidina e método de tratamento de distúrbios
BR112020026052A2 (pt) * 2018-06-21 2021-03-23 Betta Pharmaceuticals Co., Ltd forma de cristal do composto para a inibição da atividade de cdk4/6 e seu uso
US20240083917A1 (en) * 2021-01-05 2024-03-14 Shandong Xuanzhu Pharma Co., Ltd. Polycyclic Kinase Inhibitor
TW202300145A (zh) * 2021-03-24 2023-01-01 大陸商貝達藥業股份有限公司 藥物組合、包含其的試劑盒及其用途
WO2025016439A1 (zh) * 2023-07-19 2025-01-23 浙江同源康医药股份有限公司 用作cdk2/4蛋白激酶抑制剂的化合物及其应用
CN118405996B (zh) * 2024-04-23 2025-09-09 仁合益康集团有限公司 一种依伏卡塞的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4291696B2 (ja) * 2002-01-22 2009-07-08 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ２−（ピリジン−２−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
EP1948663B1 (en) 2005-10-21 2011-09-14 Exelixis, Inc. Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
RU2008145225A (ru) 2006-04-19 2010-05-27 Новартис АГ (CH) Соединения индазола и способы ингибирования cd7
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
RU2515976C2 (ru) * 2009-02-26 2014-05-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие конденсированные гетероциклические соединения и их применение в качестве ингибиторов продукции бета-амилоида
EP2970200A1 (en) * 2013-03-13 2016-01-20 Abbvie Inc. Pyridine cdk9 kinase inhibitors
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
HUE039504T2 (hu) * 2013-12-31 2019-01-28 Xuanzhu Pharma Co Ltd Kináz inhibitor és alkalmazása
CN104910137B (zh) 2014-03-10 2017-04-19 山东轩竹医药科技有限公司 Cdk激酶抑制剂
WO2016014904A1 (en) 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
CN105153119B (zh) 2015-09-11 2019-01-01 广州必贝特医药技术有限公司 吡啶嘧啶胺类化合物或吡啶吡啶胺类化合物及其应用
CN106608879A (zh) * 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
RU2680777C1 (ru) * 2018-02-14 2019-02-26 Сергей Викторович Яблочко Направляющий аппарат центробежного многоступенчатого насоса

Also Published As

Publication number Publication date
RU2732952C2 (ru) 2020-09-24
TWI696617B (zh) 2020-06-21
TW201713645A (zh) 2017-04-16
WO2016173505A1 (en) 2016-11-03
RU2017141077A (ru) 2019-05-28
EP3288931B2 (en) 2022-07-20
MX395032B (es) 2025-03-24
RU2017141077A3 (es) 2019-08-14
BR112017023225A2 (pt) 2018-08-07
DK3288931T3 (da) 2020-02-03
DK3288931T4 (da) 2022-10-24
ES2766498T3 (es) 2020-06-12
US10450316B2 (en) 2019-10-22
US20180291027A1 (en) 2018-10-11
EP3288931A1 (en) 2018-03-07
ES2766498T5 (es) 2022-11-18
EP3288931A4 (en) 2018-10-10
EP3288931B1 (en) 2019-11-06
CN107849012A (zh) 2018-03-27
CN107849012B (zh) 2021-05-25

Similar Documents

Publication Publication Date Title
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX391501B (es) Agentes inductores de apoptosis
MX2018005528A (es) Inhibidores de ret.
CO2018005381A2 (es) Inhibidores éster de acc y usos de los mismos
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
CO2017002532A2 (es) Indazoles sustituidos con bencilo como inhibidores de bub1
CY1120935T1 (el) Νεες συνθεσεις, χρησεις και μεθοδοι για την παρασκευη αυτων
BR112019012343A2 (pt) anticorpos il-11ra
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
ECSP17023281A (es) Inhibidores de mk2 y sus usos
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
ECSP17030878A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
CL2018001837A1 (es) Compuestos antiproliferativos y sus composiciones farmacéuticas y usos
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
MX2017003589A (es) Compuestos de indolinona y usos de los mismos.
CL2019001804A1 (es) Activador de nrf2.
BR112018071592A8 (pt) inibidores de erbb e usos dos mesmos